iSpecimen announced that the Company has added several new infectious disease specimen providers to its global supply network. These new collaborations will enable iSpecimen to connect researchers with additional providers of essential human tissue and biofluids required for infectious disease research. Researchers will have access to clinically collected samples, banked tissues and custom collections of biospecimens, including viral positives and health control swabs, saliva, serum and plasma. “The iSpecimen Marketplace’s large network provides access to high volumes of samples with associated data that supports infectious disease research efforts as well as the unique needs of diagnostic companies,” said Tracy Curley, iSpecimen’s CEO. “Our global network, combined with our custom project capabilities, provides researchers with diverse samples – including those from hard-to-reach populations – to advance diagnostic test and treatment development, ultimately leading to improved patient outcomes.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ISPC:
- iSpecimen Preannounces Third Quarter 2023 Revenue Increase of 60-70% Sequentially
- iSpecimen sees Q3 revenue $2.6M-$2.8M vs. $1.63M last year
- iSpecimen Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers
- iSpecimen launches next-day quote service for medical researchers, providers
- iSpecimen expands provider network to enhance support for Women’s Health